- Home
- LRMR vs EBS Comparison
LRMR vs EBS Comparison
Compare LRMR & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRMR | EBS |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 423.6M |
| IPO Year | 2014 | 2006 |
Fundamental Metrics
Financial Performance| Metric | LRMR | EBS |
|---|---|---|
| Price | $3.47 | $8.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $16.50 | $12.00 |
| AVG Volume (30 Days) | ★ 2.0M | 743.9K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | $1,816.14 | N/A |
| P/E Ratio | ★ N/A | $119.86 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.26 | $5.62 |
| 52 Week High | $6.42 | $14.06 |
Technical Indicators
Market Signals| Indicator | LRMR | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 49.58 |
| Support Level | $3.10 | $7.76 |
| Resistance Level | $3.74 | $8.78 |
| Average True Range (ATR) | 0.20 | 0.46 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 81.29 | 44.29 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.